{"title":"Selexipag: still looking for its place","authors":"Marius M. Hoeper","doi":"10.1183/13993003.01560-2024","DOIUrl":null,"url":null,"abstract":"<sec><st>Extract</st>\n<p>Selexipag, an orally available prostacyclin receptor agonist, is globally approved for the treatment of pulmonary arterial hypertension (PAH) and has also been investigated in patients with chronic thromboembolic pulmonary hypertension (CTEPH). In 2022, the <I>European Respiratory Journal</I> published the results of a randomised, double-blind, placebo-controlled trial involving 78 Japanese patients with CTEPH who were inoperable or had persistent pulmonary hypertension after pulmonary endarterectomy (PEA) or pulmonary balloon angioplasty (BPA) [1]. This study met its primary endpoint, showing a placebo-corrected change in pulmonary vascular resistance (PVR) of –93.5 dyn·s·cm<sup>–5</sup> after 20 weeks. However, no significant improvements were observed in 6-min walk distance and World Health Organization functional class (WHO-FC). Clinical worsening events occurred in one patient assigned to selexipag and one patient assigned to placebo. Based on this study, selexipag was approved for the treatment of CTEPH in Japan.</p>\n</sec>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"25 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/13993003.01560-2024","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Extract
Selexipag, an orally available prostacyclin receptor agonist, is globally approved for the treatment of pulmonary arterial hypertension (PAH) and has also been investigated in patients with chronic thromboembolic pulmonary hypertension (CTEPH). In 2022, the European Respiratory Journal published the results of a randomised, double-blind, placebo-controlled trial involving 78 Japanese patients with CTEPH who were inoperable or had persistent pulmonary hypertension after pulmonary endarterectomy (PEA) or pulmonary balloon angioplasty (BPA) [1]. This study met its primary endpoint, showing a placebo-corrected change in pulmonary vascular resistance (PVR) of –93.5 dyn·s·cm–5 after 20 weeks. However, no significant improvements were observed in 6-min walk distance and World Health Organization functional class (WHO-FC). Clinical worsening events occurred in one patient assigned to selexipag and one patient assigned to placebo. Based on this study, selexipag was approved for the treatment of CTEPH in Japan.
期刊介绍：
The European Respiratory Journal (ERJ) is the flagship journal of the European Respiratory Society. It has a current impact factor of 24.9. The journal covers various aspects of adult and paediatric respiratory medicine, including cell biology, epidemiology, immunology, oncology, pathophysiology, imaging, occupational medicine, intensive care, sleep medicine, and thoracic surgery. In addition to original research material, the ERJ publishes editorial commentaries, reviews, short research letters, and correspondence to the editor. The articles are published continuously and collected into 12 monthly issues in two volumes per year.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
